Special Issue "Immune Responses to Human Prostate Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 August 2012)
Dr. Kwong Yok Tsang
Cellular Immunology Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC-1750, Building 10, Room 8B08, Bethesda, MD 20892, USA
Phone: +1 301 496 9694
Fax: +1 301 496 2756
Interests: the role of the human immune response to tumor-associated antigens. We are working to define and develop immunodominant determinants and modifications of those determinants toward the optimal activation of human immune responses to tumor-associated antigens. Additionally, we are involved in studying mechanisms to enhance the potency of antigen-presenting cells for specific T cell activation. We are also developing immunologic methods and immunoassays to better define the efficacy of vaccine therapies for a range of human cancers.
Prostate cancer (PCa) is the most common malignancy in men in the United States and a leading cause of cancer death in North America. The American Cancer Society estimates that 217,730 men in the United States are diagnosed yearly, resulting in approximately 32,050 deaths. Immunotherapeutic approaches using peptide- or dendritic cell-based vaccines and poxviral-based vaccines have shown evidence of clinical benefit. A recently reported phase III trial of sipuleucel-T vaccine in patients with metastatic castration-resistant PCa (mCRPC) was the first trial with overall survival (OS) as the primary endpoint to demonstrate a statistically significant improvement in OS with a cell-based therapeutic vaccine. A 43-center phase II randomized controlled trial of a poxviral-based PSA-targeted vaccine (PSA-TRICOM) in mCRPC also demonstrated an improvement in median OS of 8.5 months in this patient population. These data provide additional evidence that therapeutic vaccines can lead to improved OS. It is well established that the host immune response can influence the growth of prostate cancer. A weak antitumor response may reflect the fact that tumor antigens themselves are weakly immunogenic. Alternatively, a weak host immune response may be associated with prior treatment, particularly chemotherapy or radiotherapy, a fact that should be taken into consideration when designing clinical trials that employ a combination of cancer vaccines and standard therapies for prostate cancer. This special issue will cover many topics, but its main focus will be the components of innate, adaptive, and suppressive immune responses in prostate cancer patients. Thus, we are particularly interested in reports of prostate cancer clinical trials that employ cancer vaccines and standard therapies, and that show evidence of immune response and clinical benefit.
Dr. Kwong Yok Tsang
- prostate cancer
- tumor antigens
- cancer vaccines and standard therapies
- innate immune response
- adaptive immune response
- suppressive immune response
- clinical benefit
Cancers 2013, 5(2), 569-590; doi:10.3390/cancers5020569
Received: 29 March 2013; in revised form: 16 April 2013 / Accepted: 8 May 2013 / Published: 24 May 2013| Download PDF Full-text (270 KB) | View HTML Full-text | Download XML Full-text
Article: The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T
Cancers 2013, 5(2), 511-518; doi:10.3390/cancers5020511
Received: 19 March 2013; in revised form: 19 March 2013 / Accepted: 22 April 2013 / Published: 6 May 2013| Download PDF Full-text (154 KB) | View HTML Full-text | Download XML Full-text
Review: Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
Cancers 2012, 4(4), 1333-1348; doi:10.3390/cancers4041333
Received: 24 October 2012; in revised form: 29 November 2012 / Accepted: 5 December 2012 / Published: 11 December 2012| Download PDF Full-text (432 KB) | View HTML Full-text | Download XML Full-text
Review: Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response
Cancers 2012, 4(4), 1229-1246; doi:10.3390/cancers4041229
Received: 8 October 2012; in revised form: 9 November 2012 / Accepted: 14 November 2012 / Published: 22 November 2012| Download PDF Full-text (156 KB) | View HTML Full-text | Download XML Full-text
Cancers 2012, 4(2), 420-441; doi:10.3390/cancers4020420
Received: 5 March 2012; in revised form: 2 April 2012 / Accepted: 6 April 2012 / Published: 18 April 2012| Download PDF Full-text (246 KB) | View HTML Full-text | Download XML Full-text
Cancers 2012, 4(1), 193-217; doi:10.3390/cancers4010193
Received: 13 January 2012; in revised form: 14 February 2012 / Accepted: 16 February 2012 / Published: 22 February 2012| Download PDF Full-text (243 KB) | View HTML Full-text | Download XML Full-text
Article: Clinical Investigation of the Role of Interleukin-4 and Interleukin-13 in the Evolution of Prostate Cancer
Cancers 2011, 3(4), 4281-4293; doi:10.3390/cancers3044281
Received: 24 October 2011; in revised form: 23 November 2011 / Accepted: 30 November 2011 / Published: 16 December 2011| Download PDF Full-text (491 KB) | View HTML Full-text | Download XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Last update: 25 February 2014